FRANCE FUNDS AVITA’S 200-PATIENT RECELL TRIAL
December 18th 2008 11:19
Tuesday December 16, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: VENTRACOR UP 22%, NEUREN DOWN 17%
* PEPLIN COMPLETES PHASE III SKIN CANCER TRIAL ENROLMENT
* FRANCE FUNDS AVITA’S 200-PATIENT RECELL TRIAL
* QRX BEGINS COMPARATIVE STUDY OF MOXDUOIR FOR PAIN
* $2.4m MILESTONE PAYMENT EASES ALCHEMIA’S CASH PAIN
* BIONOMICS OPTIONS TO RAISE $6.9m
* NEURODISCOVERY IN CASH PAIN OVER NSL-043
* SPACELABS TO DISTRIBUTE USCOM HEART MONITOR
* RESMED APPOINTS STEIN JACOBSEN EURO-COO
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
AVITA MEDICAL
Avita says the French Ministry of Health is funding a 200 patient medico-economics study on the impact of Recell on burn wound healing.
Avita said that the first patients were enrolled and had been treated in the study which was part of a French program “to advance the implementation of innovative technologies”.
The study is organized through the French government’s Support to Innovative and Costly Technologies program as part of the government’s effort to identify and introduce innovative, cost-effective technologies into routine medical care.
Twelve teaching and academic hospitals have been selected to participate in the study.
Avita said the primary goal was to demonstrate the medical effectiveness and economic benefits of the Recell technology to the hospital and health care system in the treatment of burns and wounds.
The safety and efficacy of Recell have been previously validated, the company said.
Avita said the program was “highly competitive” with 345 projects submitted for inclusion and only Recell and an artificial electronic heart, selected for participation and funding.
Avita chief executive officer Dr William Dolphin said the endorsement by French surgeons and the Ministry of Health was “a strong affirmation of the major medical benefits delivered by Recell to burn victims”.
Dr Dolphin said that all involved in the trial were “confident the economic benefits of the product will be clearly demonstrated in the results of the study as well.”
Avita said Pfizer has recently established a global regenerative medicine unit, Pfizer Regenerative Medicine along with initiatives for regenerative medicine from Johnson & Johnson, Glaxosmithkline, Roche, Novartis and other companies.
“Regenerative medicine is clearly the frontier of medical science,” Dr Dolphin said.
“The support by the French government and recent endorsement by key surgeons in the United Kingdom bodes well for the acceptance of Recell as the first commercially available bedside cell therapy and for its establishment as the standard of care for the treatment of burns, scar remodeling and other skin defects and injuries,” Dr Dolphin said.
Avita was up 0.1 cents or 2.63 percent to 3.9 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 59 |
| Vote |
Add To: 
subscribe to this blog